IN2004KO01960A - - Google Patents

Info

Publication number
IN2004KO01960A
IN2004KO01960A IN1960KO2004A IN2004KO01960A IN 2004KO01960 A IN2004KO01960 A IN 2004KO01960A IN 1960KO2004 A IN1960KO2004 A IN 1960KO2004A IN 2004KO01960 A IN2004KO01960 A IN 2004KO01960A
Authority
IN
India
Prior art keywords
escherichia coli
helicobacter species
zoonotic helicobacter
zoonotic
oligosaccharide
Prior art date
Application number
Inventor
Jonas Angstroem
Susann Teneberg
Juhani Saarinen
Tero Satomaa
Niamh Roche
Jari Natunen
Halina Miller-Podraza
Karl-Anders Karlsson
Maan Abul-Milh
Original Assignee
Glykos Finland Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20021275A external-priority patent/FI20021275A0/en
Priority claimed from FI20030564A external-priority patent/FI20030564A0/en
Application filed by Glykos Finland Oy filed Critical Glykos Finland Oy
Publication of IN2004KO01960A publication Critical patent/IN2004KO01960A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides a therapeutical composition comprising purified fractions of compounds being or containing a pathogen-inhibiting oligosaccharide sequence for use as a medicament. The present invention especially describes an oligosaccharide-containing substance or receptor binding to diarrheagenic Escherichia coli and/or zoonotic Helicobacter species, and use thereof in, e.g., pharmaceutical, nutritional and other compositions for prophylaxis and treatment of conditions due to the presence of Escherichia coli and/or zoonotic Helicobacter species. The invention is also directed to the use of the receptors for diagnostics of Escherichia coli and/or zoonotic Helicobacter species.
IN1960KO2004 2002-06-28 2004-12-20 IN2004KO01960A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20021275A FI20021275A0 (en) 2002-06-28 2002-06-28 Therapeutic compositions for use in the prevention or treatment of diarrhea
FI20030564A FI20030564A0 (en) 2003-04-14 2003-04-14 Substances that bind zoonotic Helicobacter species and their use

Publications (1)

Publication Number Publication Date
IN2004KO01960A true IN2004KO01960A (en) 2006-07-21

Family

ID=30001920

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1960KO2004 IN2004KO01960A (en) 2002-06-28 2004-12-20

Country Status (10)

Country Link
US (1) US20060014717A1 (en)
EP (2) EP1531832B1 (en)
JP (1) JP5219329B2 (en)
AT (1) ATE428430T1 (en)
AU (1) AU2003242799A1 (en)
DE (1) DE60327211D1 (en)
DK (1) DK1531832T3 (en)
ES (1) ES2649736T3 (en)
IN (1) IN2004KO01960A (en)
WO (1) WO2004002495A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
DK1599468T3 (en) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
EP2287166A3 (en) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
EP1675601B2 (en) † 2003-10-13 2013-04-10 Nestec S.A. Moderating the effect of endotoxins
EP1634599A1 (en) 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1629850B2 (en) 2004-08-24 2013-05-22 N.V. Nutricia Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
BRPI0707620A2 (en) * 2006-02-10 2011-05-10 Nestec Sa oligosaccharide mixture
US20080208486A1 (en) * 2006-03-23 2008-08-28 Jari Natunen Integrated System, Device and Use Thereof
JP5077623B2 (en) * 2006-03-30 2012-11-21 Ｄｉｃ株式会社 Method for producing cashew oil-modified solid phenolic resin and rubber composition
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
FI20060946A0 (en) * 2006-10-26 2006-10-26 Glykos Finland Oy Influenza virus nucleic acids and peptides
FI20065800A0 (en) * 2006-12-13 2006-12-13 Glykos Finland Oy Polyvalent bioconjugates
FI20075030A0 (en) * 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Method of modifying cells
FI20070471A0 (en) * 2007-06-13 2007-06-13 Glykos Finland Oy Ravinnelisäkompositiota
JP5597890B2 (en) * 2007-06-25 2014-10-01 ディーエスエム アイピー アセッツ ビー．ブイ． New prebiotics
CA2698374C (en) 2007-09-07 2018-04-03 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
WO2009060073A1 (en) * 2007-11-08 2009-05-14 Nestec S.A. Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
MY169947A (en) 2008-03-14 2019-06-19 Nestle Sa Preparation of 6-aminocaproic acid from 5-formyl valeri c acid
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
WO2009149149A1 (en) * 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
GB0817908D0 (en) 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
WO2010041746A1 (en) * 2008-10-10 2010-04-15 財団法人野口研究所 Helicobacter pylori bacterium proliferation inhibitor
FI20080665A0 (en) 2008-12-18 2008-12-18 Glykos Finland Oy Natural saccharide compositions
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
FI20105824A0 (en) * 2010-07-26 2010-07-26 Suomen Punainen Risti Veripalv Use of blood group status IV
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2658399B2 (en) 2010-12-31 2024-02-28 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides for use in treating and/or preventing enteric rotavirus infection
WO2012112716A1 (en) * 2011-02-16 2012-08-23 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP2844301A2 (en) * 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
EP2857410A1 (en) * 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
CN103622901B (en) * 2013-11-21 2016-01-20 广州立白企业集团有限公司 Composition of skin cleanser of a kind of energy regulation of skin microecological balance and preparation method thereof
CN107001528A (en) 2014-07-09 2017-08-01 米德瑞（美国）有限公司 Oligosaccharide composition and preparation method thereof
EP3177325B1 (en) 2014-08-08 2020-04-01 GlaxoSmithKline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US9492473B2 (en) * 2015-01-26 2016-11-15 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
EP3354282B1 (en) 2015-01-26 2020-12-30 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
CA2975095A1 (en) 2015-01-26 2016-08-04 Cadena Bio, Inc. Oligosaccharide compositions for use as animal feed and methods of producing thereof
CN107846957A (en) 2015-03-05 2018-03-27 雀巢产品技术援助有限公司 For improving baby or child's stool consistency or the composition of frequency
US10709721B2 (en) 2015-03-05 2020-07-14 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children
CN116270718A (en) 2015-04-23 2023-06-23 Dsm营养产品有限责任公司 Glycan therapeutic and methods of treatment
EP3288389A4 (en) 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
EP3337321A4 (en) 2015-08-19 2019-07-17 President and Fellows of Harvard College Lipidated psa compositions and methods
CN105410913B (en) * 2015-12-01 2018-06-01 辽宁三合酒业有限公司 A kind of preparation method of oligochitosan oral cavity cleaning lozenge
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
AU2017307455B2 (en) 2016-08-04 2023-07-06 Société des Produits Nestlé S.A. Nutritional compositions with 2FL and LNnT for use in preventing and/or treating non-rotavirus diarrhea by acting on the gut microbiota dysbiosis
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis
CN108018805B (en) * 2017-12-31 2018-12-04 江苏来德福汽车部件有限公司 A kind of intelligent mobile guardrail of solar energy
US20210298328A1 (en) * 2018-08-08 2021-09-30 Mars, Incoroprated Pet food products comprising oligosaccharides and methods of use
CN109212227B (en) * 2018-09-07 2021-07-16 深圳格道糖生物技术有限公司 Product for screening and evaluating liver disease/cirrhosis related to saliva specific glycoprotein sugar chain structure and application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225330A (en) * 1988-08-01 1993-07-06 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic kit and diagnostic method utilizing carbohydrate receptors
US5217715A (en) * 1988-08-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Carbohydrate receptor for bacteria and method for use thereof
MX9304638A (en) * 1992-07-31 1994-05-31 Neose Pharm Inc COMPOSITION TO TREAT AND INHIBIT GASTRIC AND DUODENAL ULCERS.
WO1996002255A1 (en) * 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Medicinal composition containing sialic acid derivative
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US6045854A (en) * 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
NL1010770C2 (en) * 1998-12-09 2000-06-13 Nutricia Nv Preparation containing oligosaccharides and probiotics.
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
SE9904581D0 (en) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and its use
FI20010118A (en) * 2001-01-19 2002-07-20 Carbion Oy New receptors for helicobacter pylori and their use
ATE429233T1 (en) * 2001-06-29 2009-05-15 Glykos Finland Oy USE OF AT LEAST ONE GLYCOINHIBITOR SUBSTANCE AGAINST INFECTIOUS DISEASES

Also Published As

Publication number Publication date
US20060014717A1 (en) 2006-01-19
AU2003242799A1 (en) 2004-01-19
EP2272522A2 (en) 2011-01-12
EP1531832A1 (en) 2005-05-25
JP5219329B2 (en) 2013-06-26
WO2004002495A1 (en) 2004-01-08
ES2649736T3 (en) 2018-01-15
ATE428430T1 (en) 2009-05-15
EP2272522A3 (en) 2011-04-20
EP2272522B1 (en) 2017-09-06
DK1531832T3 (en) 2009-07-27
DE60327211D1 (en) 2009-05-28
JP2006506329A (en) 2006-02-23
EP1531832B1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
IN2004KO01960A (en)
EP1539228A4 (en) Novel composition and methods for the treatment of immune related diseases
GEP20074197B (en) 5ht2c receptor modulators
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
IL145830A0 (en) Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
AU2003217055A1 (en) Protein for use in hypoxia related conditions
GT200200188A (en) PREPARATION AND USE OF IMIDAZOL DERIVATIVES FOR THE TREATMENT OF OBESITY
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
MX9203050A (en) TRIPTAMINE ANALOG COMPOUNDS.
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HK1078466A1 (en) Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance
PL2018169T3 (en) Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
RU2004127960A (en) APPLICATION OF VITAMIN D COMPOSITIONS
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DK0583421T3 (en) Substituted dibenzoxazepine compounds, drugs and methods of use
ES2194677T3 (en) SUSPENSIONS OF TROVAFLOXACINE ADMINISTRATION VIA ORAL.
IL165220A0 (en) Novel compounds, their use and preparation
EE05182B1 (en) Substituted Homopiperidobenzimidazole Analog, Method for its Preparation and Pharmaceutical Composition Containing it
BR0213696A (en) Nicotinic Acetylcholine Receptor Agonists In The Treatment Of Restless Leg Syndrome
GB9516967D0 (en) Pharmaceutical composition
BR0314555A (en) Epothilone derivatives for the treatment of multiple myeloma
GB9211277D0 (en) Pharmaceutical compositions
GB9926301D0 (en) Novel compounds